Thorsten Kessler
@thokessl.bsky.social
Cardiologist, Clinician Scientist @ TUM, Munich; Husband, father of 3; supports 🇺🇦; against racism and 🌎 warming
Reposted by Thorsten Kessler
Multiple areas are identified where PRS may have utility & indeed where translational studies (eg pragmatic trials) may be warranted. Importantly no one sees PRS as a standalone screening tool. Rather PRS is combined with other factors to guide healthcare. www.nature.com/articles/s41...
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps - Nature ...
As polygenic risk scores move closer to widespread clinical use, this Perspective summarizes the benefits, risks and challenges to be overcome.
www.nature.com
October 21, 2023 at 3:13 PM
Multiple areas are identified where PRS may have utility & indeed where translational studies (eg pragmatic trials) may be warranted. Importantly no one sees PRS as a standalone screening tool. Rather PRS is combined with other factors to guide healthcare. www.nature.com/articles/s41...
Reposted by Thorsten Kessler
Neue Daten aus Hanover & Göttingen zeigen eine sehr gute Immunatwort nach XBB.1.5-adaptiertem Booster (Biontech). V.a. sehr gute Neutralisation aller XBB-Linien (inkl. Eris) & BA.2.86 (Pirola). Sehr ähnliche Daten hatte auch Moderna vorgelegt.
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
October 6, 2023 at 4:16 PM
Neue Daten aus Hanover & Göttingen zeigen eine sehr gute Immunatwort nach XBB.1.5-adaptiertem Booster (Biontech). V.a. sehr gute Neutralisation aller XBB-Linien (inkl. Eris) & BA.2.86 (Pirola). Sehr ähnliche Daten hatte auch Moderna vorgelegt.
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...